FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP)

Leukemia. 2004 Dec;18(12):2038-40. doi: 10.1038/sj.leu.2403536.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD / metabolism*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Humans
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Prednisone / administration & dosage
  • Prognosis
  • Receptors, IgG / metabolism*
  • Rituximab
  • Survival Rate
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • Fc gamma receptor IIB
  • Receptors, IgG
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol